The Amber Signal Book | August 2026
Make a rare diagnosis easier to recognize, route, and support
Appendix Cancer Awareness Month 2026 gives health systems a practical leadership test: can an uncommon, complex diagnosis move through pathology, oncology, specialty referral, treatment planning, navigation, and research access without the patient becoming the project manager? Awareness matters most when it changes the pathway.
Turn it amber
Why Appendix Cancer Awareness Month matters in 2026
The ACPMP Research Foundation confirms August as Appendix Cancer Awareness Month 2026. Its campaign uses amber to make a rare cancer more visible, and its 2026 programming includes education, patient voices, community proclamations, and Light Up Amber activities. Healthcare organizations should support that visibility, then pair it with a measurable care-delivery commitment.
The National Cancer Institute describes two main groups: epithelial appendiceal cancer and neuroendocrine appendiceal cancer. Epithelial tumors may produce mucin, and a buildup of mucin in the abdomen can cause pseudomyxoma peritonei, or PMP. Tumor type, grade, spread, and resectability influence the care plan, so a generic “colon cancer” pathway is not an adequate substitute for disease-specific review.
The five-node rare cancer referral circuit
For executives, the highest-value intervention is a reliable transition from an unexpected finding to expert review. The circuit below should be designed across emergency medicine, general surgery, radiology, pathology, oncology, surgical oncology, navigation, social work, and referring clinicians. Every node needs a named owner, a time expectation, and a closed-loop handoff.
Recognize
Give frontline teams concise education on unusual operative, imaging, pathology, or symptom patterns and a clear escalation route.
Classify
Protect specimen handling, complete pathology review, and precise documentation of histology, grade, margins, and disease extent.
Refer
Trigger navigator outreach and rapid consultation with clinicians who regularly manage appendiceal tumors and peritoneal disease.
Convene
Use multidisciplinary review to align surgery, medical oncology, radiology, pathology, supportive care, and the patient’s goals.
Stay connected
Close loops on records, travel, authorizations, second opinions, treatment decisions, symptoms, and long-term follow-up.
ACPMP recommends that patients consult a clinician experienced in appendix cancer and PMP before treatment, while noting that its specialist resource is informational and not an endorsement. A health system can operationalize that principle by maintaining an approved referral directory, a transfer checklist, an escalation contact, and a method to return recommendations to the local care team.
Eight executive commitments that outlast August
A board-ready appendix cancer pathway scorecard
| Pathway domain | Leading indicator | Outcome signal | Executive question |
|---|---|---|---|
| Diagnosis | Time from final pathology to patient notification and referral order | Cases with complete pathology elements and expert review when indicated | Can every unexpected diagnosis be traced to a closed handoff? |
| Specialty access | Time from referral to accepted consultation | Consult completion, second-opinion completion, and avoidable delay | Which barrier most often prevents expert review? |
| Navigation | Outreach within one business day; documented barrier screen | Records received, authorization completed, travel plan, and follow-up continuity | Are patients coordinating tasks the system should own? |
| Learning | Multidisciplinary review and research-option documentation | Pathway variance closure, trial referral, experience, and equity trends | What changed in the operating model this quarter? |
This table can be scrolled horizontally by keyboard or touch on smaller screens. Define measures locally, protect privacy, and interpret small rare-cancer samples carefully. Use patient-level review when aggregate rates could mislead.
Turn August amber with a four-week activation sequence
ACPMP’s Light Up Amber campaign creates a visible invitation to learn. A hospital can illuminate a building, share the official campaign, and recognize patients and caregivers. The strongest activation also leaves behind an operational improvement that can be audited in September.
Map the current journey
Convene a patient, caregiver, surgeon, pathologist, oncologist, navigator, access leader, and community clinician. Identify where information or ownership is lost.
Run one tracing exercise
Use a de-identified recent case to test notification, records transfer, referral acceptance, authorization, travel support, and return communication.
Educate with precision
Share ACPMP and NCI resources, display amber, invite expert teaching, and give staff one actionable referral route instead of an unsupported symptom checklist.
Publish the next change
Assign the owner, target, due date, and measure for one pathway fix. Report progress to executive leadership and patient advisors within 90 days.
Executive conclusion: visibility should open a door
Appendix Cancer Awareness Month 2026 is a chance to replace a rare-disease scavenger hunt with a defined response. The goal is not to make every clinician an appendix cancer specialist. It is to make every unexpected finding recognizable, every handoff owned, every specialist consultation reachable, every patient supported, and every learning opportunity visible to leadership.
Boards should expect a named pathway owner, a documented referral standard, timely patient navigation, and quarterly review of diagnostic delay, specialist access, unresolved barriers, and corrective action.
That operating model connects directly with The Healthcare Executive’s guidance on rare disease strategy, executive cancer control, oncology access and navigation, patient experience measurement, and high-performing healthcare organizations.